ClinicalTrials.gg
CompletedNCT01497262Updated Mar 19, 2015Results posted

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

A Phase 3 interventional study of Fingolimod in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 29 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-03-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
18th of 34
162 · median 167
Started
2012
with 3 others
Phase 3
12 of 34
1 open now
Registered
18th of 34
by date
Lead sponsor
20 of 34
Novartis Pharmaceuticals

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 18th largest by enrollment, is one of 4 that started in 2012, is one of 12 in phase 3, and was the 18th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This 4 month, open-label study will evaluate the safety and tolerability of fingolimod 0.5 mg in patients with relapsing-remitting multiple sclerosis (RRMS) and generate additional data in Multiple Sclerosis (MS) patient population that closely resembles the clinical population seen in routine medical care.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • Relapsing-Remitting
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with relapsing remitting Multiple Sclerosis
  • Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5.

Exclusion criteria

Exclusion Criteria:

  • Patients with MS other than relapsing remitting MS
  • Patients with a history of chronic disease of the immune system other than MS, which requires systemic treatment, or a known immunodeficiency syndrome.
  • Patients who have been treated with:

    • systemic or immunoglobulins within 1 month prior to baseline;
    • immunosuppressive medications within 3 months prior to baseline;
    • monoclonal antibodies within 3 months prior to baseline;
    • cladribine, mitoxantrone or alemtuzumab at any time.
  • Uncontrolled diabetes mellitus at screening
  • Diagnosis of macular edema during Screening Phase
  • Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, , infection or to have positive antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.
  • Patients who have received total lymphoid irradiation or bone marrow transplantation.
  • Patients with certain cardiovascular conditions and/or findings in the screening
  • Patients with certain liver conditions
  • Pregnant confirmed by a positive pregnancy test t or nursing (lactating) women
  • Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Open-label fingolimod 0.5 mg, taken orally once daily for 4 months

    Drug: Fingolimod

Interventions

  • Fingolimod will be supplied as 0.5mg capsules in bottles of 35.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Any Adverse Event was defined as occurrence of any symptom regardless of intensity grade, Serious Adverse Event (SAEs) assessed as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in persistent or significant disability/incapacity

    Time frame: 28 weeks

Secondary outcomes

  1. Number (%) of Patients With AE of Special Interest Including Bradyarrhythmia, BP Increase, Liver Transaminase Elevations, Infections , Macula Oedema.

    The incidence of events in special areas of safety interest (including bradyarrhythmias, BP increase, liver function, infections and macular oedema) were assessed by the nature and frequency of AE reporting. These areas of special interest have been identified and potential risks of fingolimod based on knowledge from clinical trials and post-marketing reporting.

    Time frame: 4 months

07

Results

Posted Mar 19, 2015

Participant flow

Participant flow — Overall Study
MilestoneFingolimod 0.5 mg
Started162
Completed151
Not completed11
Withdrew: Abnormal lab values4
Withdrew: Abnormal test procedure result1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject2
Withdrew: Adverse event2
Withdrew: Protocol violation1

Outcome measures

SecondaryNumber (%) of Patients With AE of Special Interest Including Bradyarrhythmia, BP Increase, Liver Transaminase Elevations, Infections , Macula Oedema.

The incidence of events in special areas of safety interest (including bradyarrhythmias, BP increase, liver function, infections and macular oedema) were assessed by the nature and frequency of AE reporting. These areas of special interest have been identified and potential risks of fingolimod based on knowledge from clinical trials and post-marketing reporting.

Time frame:
4 months
Reported as:
Number · Percent of Participants
Number (%) of Patients With AE of Special Interest Including Bradyarrhythmia, BP Increase, Liver Transaminase Elevations, Infections , Macula Oedema.
Percent of ParticipantsFingolimod 0.5 mg
Bradyarrhythmias8.6
Blood pressure increase0.6
Hypertension2.5
Liver Transaminase evaluations3.7
Infections28.4
Macula Oedema0
PrimaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability

Any Adverse Event was defined as occurrence of any symptom regardless of intensity grade, Serious Adverse Event (SAEs) assessed as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in persistent or significant disability/incapacity

Time frame:
28 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
ParticipantsFingolimod 0.5 mg
Adverse Events (AE)100
Serious Adverse Event (SAE)12
Deaths0

Adverse events

Collected over Weeks 2,8, 16 and end of study visit. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod 0.5 mg—12/162 (7.4%)63/162 (38.9%)
Most frequent serious events
Most frequent serious events
EventFingolimod 0.5 mg
Multiple sclerosis relapseNervous system disorders3/162
GastroenteritisInfections and infestations2/162
LeukopeniaBlood and lymphatic system disorders1/162
Gastroenteritis viralInfections and infestations1/162
Urinary tract infectionInfections and infestations1/162
Fibrin D dimer increasedInvestigations1/162
White blood cell count decreasedInvestigations1/162
Optic neuritisNervous system disorders1/162
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/162
HypertensionVascular disorders1/162
Most frequent other events
Showing 10 of 14
Most frequent other events
EventFingolimod 0.5 mg
HeadacheNervous system disorders22/162
LymphopeniaBlood and lymphatic system disorders17/162
FatigueGeneral disorders10/162
DiarrhoeaGastrointestinal disorders8/162
Upper respiratory tract infectionInfections and infestations8/162
BradycardiaCardiac disorders6/162
NauseaGastrointestinal disorders5/162
Back painMusculoskeletal and connective tissue disorders5/162
DizzinessNervous system disorders5/162
AnxietyPsychiatric disorders5/162

Baseline characteristics

The Enrolled Set (ENR) included all patients who signed the informed consent and enrolled in study

Age, Continuous
Age, Continuous(Years)Fingolimod 0.5 mg
Mean37.3 ± 9.67
Age, Customized
Age, Customized(Participants)Fingolimod 0.5 mg
<18 years0
18-30 years47
31-40 years60
41-55 years47
56-65 years8
>65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod 0.5 mg
Female114
Male48
08

Study locations

29 sites
  • Novartis Investigative Site
    Caba, Buenos Aires 1425, Argentina
  • Novartis Investigative Site
    Guaymallen, Mendoza M5507XAD, Argentina
  • Novartis Investigative Site
    San Miguel de Tucuman, Tucumán T4000DPB, Argentina
  • Novartis Investigative Site
    San Miguel de Tucumán, Tucumán 4000, Argentina
  • Novartis Investigative Site
    Cordoba, X5004CDT, Argentina
  • Novartis Investigative Site
    Salta, A4400ANG, Argentina
  • Novartis Investigative Site
    Salta, A4400BKZ, Argentina
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20270-004, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 21941-590, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90610-000, Brazil
  • Novartis Investigative Site
    Barranquilla, Atlantico, Colombia
  • Novartis Investigative Site
    Bogotá, Cundinamarca 110111, Colombia
  • Novartis Investigative Site
    Bogotá, 00000, Colombia
  • Novartis Investigative Site
    Bogotá, Colombia
  • Novartis Investigative Site
    Cali, Colombia
  • Novartis Investigative Site
    Amman, 11942, Jordan
  • Novartis Investigative Site
    Irbid, 22110, Jordan
  • Novartis Investigative Site
    Kuala Lumpur, 50586, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Penang, 10990, Malaysia
  • Novartis Investigative Site
    Mexico, Distrito Federal 06700, Mexico
  • Novartis Investigative Site
    México, Distrito Federal 10700, Mexico
  • Novartis Investigative Site
    Monterrey, Nuevo León 64060, Mexico
  • Novartis Investigative Site
    San Nicolas De Los Garza, Nuevo León 66480, Mexico
  • Novartis Investigative Site
    San Luis Potosí, 78240, Mexico
  • Novartis Investigative Site
    Panama City, Panamá, Panama
  • Novartis Investigative Site
    La Perla, Callao 04, Peru
  • Novartis Investigative Site
    Jesus Maria, Lima 11, Peru
  • Novartis Investigative Site
    San Isidro, Lima 27, Peru
09

References and documents

Publications

  • Ordonez-Boschetti L, Rey R, Cruz A, Sinha A, Reynolds T, Frider N, Alvarenga R. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study. Adv Ther. 2015 Jul;32(7):626-35. doi: 10.1007/s12325-015-0224-2. Epub 2015 Jul 14. Erratum In: Adv Ther. 2015 Jul;32(7):636. doi: 10.1007/s12325-015-0230-4. PubMed 26170105 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2011
First posted
Dec 22, 2011
Start
Feb 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Mar 19, 2015
Last update
Mar 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01497262
Responsible party
Sponsor
First posted
Dec 22, 2011
Start date
Feb 2012
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Mar 19, 2015
Last update
Mar 19, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion